Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

2.

The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.

Obermeier HL, Riedl J, Ay C, Koder S, Quehenberger P, Bartsch R, Kaider A, Zielinski CC, Pabinger I.

Res Pract Thromb Haemost. 2019 May 6;3(3):503-514. doi: 10.1002/rth2.12197. eCollection 2019 Jul.

3.

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.

Lambertini M, Preusser M, Zielinski CC.

ESMO Open. 2019 Jun 12;4(Suppl 3):e000501. doi: 10.1136/esmoopen-2019-000501. eCollection 2019. No abstract available.

4.

How I treat cancer special issue.

Zielinski CC.

ESMO Open. 2019 May 1;4(Suppl 2):e000514. doi: 10.1136/esmoopen-2019-000514. eCollection 2019. No abstract available.

5.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
6.

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center.

Füreder LM, Widhalm G, Gatterbauer B, Dieckmann K, Hainfellner JA, Bartsch R, Zielinski CC, Preusser M, Berghoff AS.

Clin Exp Metastasis. 2018 Dec;35(8):727-738. doi: 10.1007/s10585-018-9947-1. Epub 2018 Nov 12.

7.

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.

Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC.

ESMO Open. 2018 Aug 20;3(5):e000368. doi: 10.1136/esmoopen-2018-000368. eCollection 2018. Review. Erratum in: ESMO Open. 2019 Mar 11;4(2):e000368corr1.

8.

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells.

Bauer K, Berger D, Zielinski CC, Valent P, Grunt TW.

Oncotarget. 2018 May 29;9(41):26491-26506. doi: 10.18632/oncotarget.25474. eCollection 2018 May 29.

9.

A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.

Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, Di Nisio M, Cesarman-Maus G, Kraaijpoel N, Zielinski CC, Büller HR, Ay C.

Lancet Haematol. 2018 Jul;5(7):e289-e298. doi: 10.1016/S2352-3026(18)30063-2. Epub 2018 Jun 7. Erratum in: Lancet Haematol. 2018 Jun 15;:.

10.

DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients.

Heller G, Altenberger C, Steiner I, Topakian T, Ziegler B, Tomasich E, Lang G, End-Pfützenreuter A, Zehetmayer S, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

J Pathol. 2018 Aug;245(4):387-398. doi: 10.1002/path.5079. Epub 2018 Jun 20.

11.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.

12.

Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region.

Rolfo C, Zielinski CC.

Ann Thorac Med. 2017 Oct-Dec;12(4):219-220. doi: 10.4103/atm.ATM_225_17. No abstract available.

13.

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart MJ, de Vries EGE, Latino NJ, Douillard JY, Cherny NI.

ESMO Open. 2017 Oct 9;2(4):e000216. doi: 10.1136/esmoopen-2017-000216. eCollection 2017.

14.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

15.

Educational video: the role of PD-L1 in the local tumour microenvironment.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2017 Feb 1;1(6):e000137. doi: 10.1136/esmoopen-2016-000137. eCollection 2016.

16.

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.

Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC.

ESMO Open. 2017 Jul 16;2(3):e000166. doi: 10.1136/esmoopen-2017-000166. eCollection 2017.

17.

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel.

Bianconi D, Heller G, Spies D, Herac M, Gleiss A, Liebmann-Reindl S, Unseld M, Kieler M, Scheithauer W, Streubel B, Zielinski CC, Prager GW.

Sci Rep. 2017 Jul 7;7(1):4851. doi: 10.1038/s41598-017-04743-0.

18.

Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients.

Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12707. Epub 2017 May 10.

PMID:
28488812
19.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

20.

Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease.

Kieler M, Scheithauer W, Zielinski CC, Chott A, Al-Mukhtar A, Prager GW.

ESMO Open. 2016 Dec 15;1(6):e000084. doi: 10.1136/esmoopen-2016-000084. eCollection 2016.

21.

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.

Gschwantler-Kaulich D, Tan YY, Fuchs EM, Hudelist G, Köstler WJ, Reiner A, Leser C, Salama M, Attems J, Deutschmann C, Zielinski CC, Singer CF.

PLoS One. 2017 Mar 2;12(3):e0172911. doi: 10.1371/journal.pone.0172911. eCollection 2017.

22.

Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M.

Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290.

23.

SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.

Altenberger C, Heller G, Ziegler B, Tomasich E, Marhold M, Topakian T, Müllauer L, Heffeter P, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.

24.

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M.

Eur Radiol. 2017 Aug;27(8):3167-3173. doi: 10.1007/s00330-016-4707-6. Epub 2017 Jan 3.

25.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

26.

CSCO joins ESMO Open-Cancer Horizons.

Zielinski CC, Wu YL.

ESMO Open. 2016 Nov 18;1(5):e000120. eCollection 2016. No abstract available.

27.

AIOM chooses ESMO Open-Cancer Horizons as its official journal: a warm welcome from ESMO Open.

Zielinski CC, Pinto C.

ESMO Open. 2016 Jul 1;1(4):e000080. eCollection 2016. No abstract available.

28.

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC.

ESMO Open. 2016 Jul 4;1(4):e000066. eCollection 2016.

29.

Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2016 Apr 12;1(3):e000056. eCollection 2016.

30.

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.

Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M.

ESMO Open. 2016 Mar 16;1(2):e000024. eCollection 2016.

31.

ESMO Open-Cancer Horizons and the future of oncology.

Zielinski CC.

ESMO Open. 2016 Jan 18;1(1):e000008. eCollection 2016. No abstract available.

32.

Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma.

Unseld M, Scheithauer W, Weigl R, Kornek G, Stranzl N, Bianconi D, Brunauer G, Steger G, Zielinski CC, Prager GW.

J Gastrointest Oncol. 2016 Aug;7(4):588-94. doi: 10.21037/jgo.2016.05.01.

33.

Sustained Response to Vemurafenib in a BRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient.

Prager GW, Koperek O, Mayerhoefer ME, Muellauer L, Wrba F, Niederle B, Zielinski CC, Raderer M.

Thyroid. 2016 Oct;26(10):1515-1516. Epub 2016 Sep 27. No abstract available.

PMID:
27532222
34.

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, Datlinger P, Byrgazov K, Bock C, Mannhalter C, Hörmann G, Sperr WR, Lion T, Zielinski CC, Valent P, Zöchbauer-Müller S.

Leukemia. 2016 Sep;30(9):1861-8. doi: 10.1038/leu.2016.143. Epub 2016 May 23.

35.

Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.

36.

Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy.

Wilfinger N, Austin S, Scheiber-Mojdehkar B, Berger W, Reipert S, Praschberger M, Paur J, Trondl R, Keppler BK, Zielinski CC, Nowikovsky K.

Oncotarget. 2016 Jan 12;7(2):1242-61. doi: 10.18632/oncotarget.6233.

37.

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients.

Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer W, Zielinski CC, Pabinger I, Ay C, Prager GW.

Thromb Res. 2015 Nov;136(5):865-9. doi: 10.1016/j.thromres.2015.08.010. Epub 2015 Aug 28.

38.

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M.

Clin Exp Metastasis. 2015 Oct;32(7):729-37. doi: 10.1007/s10585-015-9740-3. Epub 2015 Aug 25.

PMID:
26303828
39.

In vivo Tube Assay: An Optimised Protocol of the Directed in vivo Angiogenesis Assay by Implementing Immunohistochemistry.

Unseld M, Breuss JM, Pausz C, Pablik E, Schabbauer G, Zielinski CC, Uhrin P, Prager GW.

J Vasc Res. 2015;52(2):116-26. doi: 10.1159/000434751. Epub 2015 Jul 31.

PMID:
26277802
40.

Effects of cilengitide in osteoclast maturation and behavior.

Chillà A, Bianconi D, Geetha N, Dorda A, Poettler M, Unseld M, Sykoutri D, Redlich K, Zielinski CC, Prager GW.

Exp Cell Res. 2015 Sep 10;337(1):68-75. doi: 10.1016/j.yexcr.2015.07.018. Epub 2015 Jul 21.

PMID:
26209605
41.

Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.

Preusser M, Berghoff AS, Koller R, Zielinski CC, Hainfellner JA, Liebmann-Reindl S, Popitsch N, Geier CB, Streubel B, Birner P.

Eur J Cancer. 2015 Sep;51(13):1803-11. doi: 10.1016/j.ejca.2015.06.107. Epub 2015 Jul 8.

PMID:
26164066
42.

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Grunt TW, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, Graf A, Bilban M, Posch M, Hoermann G, Mayerhofer M, Eisenwort G, Zielinski CC, Selzer E, Valent P.

Am J Cancer Res. 2015 Jan 15;5(2):560-74. eCollection 2015.

43.

Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P.

J Hematol Oncol. 2015 Feb 25;8:16. doi: 10.1186/s13045-015-0113-9. Review.

44.

A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors.

Zielinski CC.

Transl Lung Cancer Res. 2014 Dec;3(6):406-7. doi: 10.3978/j.issn.2218-6751.2014.08.07.

45.

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R.

Breast Care (Basel). 2014 Oct;9(5):344-8. doi: 10.1159/000368330. Erratum in: Breast Care (Basel). 2016 Feb;11(1):20.

46.

FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.

Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T.

Clin Colorectal Cancer. 2015 Jun;14(2):91-8. doi: 10.1016/j.clcc.2014.12.003. Epub 2014 Dec 24.

PMID:
25666295
47.

Novel agents have a significant impact on survival of patients with multiple myeloma.

Lamm W, Eder S, Bojic M, Zielinski CC, Drach J.

Wien Klin Wochenschr. 2015 Feb;127(3-4):92-7. doi: 10.1007/s00508-014-0605-6. Epub 2015 Jan 22.

PMID:
25609569
48.

DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers.

Heller G, Altenberger C, Schmid B, Marhold M, Tomasich E, Ziegler B, Müllauer L, Minichsdorfer C, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Fong KM, Wright CM, Yang IA, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Oncotarget. 2015 Jan 1;6(1):394-408.

49.

Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol.

Pluschnig U, Haslik W, Bayer G, Soleiman A, Bartsch R, Lamm W, Steger GG, Zielinski CC, Mader RM.

Support Care Cancer. 2015 Jun;23(6):1741-8. doi: 10.1007/s00520-014-2535-2. Epub 2014 Nov 30.

PMID:
25433440
50.

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W.

Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct 29.

Supplemental Content

Loading ...
Support Center